Adjuvanted influenza vaccines for pediatric use
View Patent ↗An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.
1. A method for raising an immune response to an influenza B virus strain in a human child of up to 72 months of age, comprising a step of administering to the child an immunogenic composition comprising: (i) an influenza B virus strain antigen; and (ii) an adjuvant, wherein the adjuvant comprises an oil-in-water emulsion in which the majority of oil droplets have a diameter of less than 1 μm and the oil droplets comprise squalene.
2. The method of claim 1 , wherein the child is less than 36 months old.
3. The method of claim 1 , wherein the child is at least 6 months old.
4. The method of claim 2 , wherein the child is at least 6 months old but less than 36 months old.
5. The method of claim 1 , wherein the immunogenic composition includes a subtype H3N2 influenza A strain antigen and the child receives one dose of vaccine.
6. The method of claim 1 , wherein the immunogenic composition includes a subtype H1N1 influenza A strain antigen and the child receives more than one dose of vaccine.
7. The method of claim 1 , wherein the child receives more than one dose of vaccine.